Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma

Pourhamzeh, Mahsa; Asadian, Samieh; Mirzaei, Hamed; Minaei, Azita; Shahriari, Elahe; Shpichka, Anastasia; Es, Hamidreza Aboulkheyr; Timashev, P. S.; Hassan, Moustapha; Vosough, Massoud

doi:10.1007/s11010-022-04483-4

Cited by 10 publications

(6 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it proposes the concept that CTLA‐4 competes against CD28 for ligands, thus serving as an antagonist of CD28‐mediated costimulation 24 (Figure 1). Importantly, the expression of CTLA‐4 is strongly upregulated in HCC patients 25 . The above studies suggest that CTLA‐4 may play a pivotal role in immunosuppression and the development of HCC.…”

Section: Introductionmentioning

confidence: 81%

See 1 more Smart Citation

Blockade of PD‐1 and CTLA‐4: A potent immunotherapeutic approach for hepatocellular carcinoma

Hou,

Xu,

et al. 2023

BioFactors

View full text Add to dashboard Cite

Immune checkpoints (ICPs) can promote tumor growth and prevent immunity‐induced cancer cell apoptosis. Fortunately, targeting ICPs, such as programmed cell death 1 (PD‐1) or cytotoxic T lymphocyte associated protein 4 (CTLA‐4), has achieved great success in the past few years and has gradually become an effective treatment for cancers, including hepatocellular carcinoma (HCC). However, many patients do not respond to ICP therapy due to acquired resistance and recurrence. Therefore, clarifying the specific mechanisms of ICP in the development of HCC is very important for enhancing the efficacy of anti‐PD‐1 and anti‐CTLA‐4 therapy. In particular, antigen presentation and interferon‐γ (IFN‐γ) signaling were reported to be involved in the development of resistance. In this review, we have explained the role and regulatory mechanisms of ICP therapy in HCC pathology. Moreover, we have also elaborated on combinations of ICP inhibitors and other treatments to enhance the antitumor effect. Collectively, recent advances in the pharmacological targeting of ICPs provide insights for the development of a novel alternative treatment for HCC.

show abstract

Section: Introductionmentioning

confidence: 81%

“…Importantly, the expression of CTLA-4 is strongly upregulated in HCC patients. 25 The above studies suggest that CTLA-4 may play a pivotal role in immunosuppression and the development of HCC.…”

Section: Introductionmentioning

confidence: 93%

Blockade of PD‐1 and CTLA‐4: A potent immunotherapeutic approach for hepatocellular carcinoma

Hou,

Xu,

et al. 2023

BioFactors

View full text Add to dashboard Cite

show abstract

“…Previous studies reported that BSG could enhance malignant tumor behaviors via immunosuppression in the liver tumor microenvironment [19,20]. To explore whether ENST00000353555 exerts isoform-specific regulation on the immunosuppression, we compared the correlation of total BSG expression and ENST00000353555 with 24 immunosuppressive genes identified in a previous publication [21], including VTCN1, ARG1, EDNRB, IL12A, CD274, HAVCR2, IL10, CTLA4, SLAMF7, TIGIT, BTLA, IDO1, LAG3, PDCD1, IL13, IL4, KIR2DL1, KIR2DL3, ADORA2A, C10orf54, VEGFB, VEGFA, CD276, and TGFB1, in primary liver cancer cases in TCGA-LIHC (Figure 3).…”

Section: Total Bsg and Enst00000353555 Have Great Differences In The ...mentioning

confidence: 99%

BSG Isoform 2 (ENST00000353555) Is a Better Component Than Total BSG Expression in Generating Prognostic Signature for Overall Survival of Liver Cancer

Xiong,

Deng

2024

Cureus

View full text Add to dashboard Cite

“…Other approaches, like surgery, chemotherapy, and radiotherapy, are associated with several serious side effects, such as the toxicity of the different body systems (e.g., the immune system) and the advancement of secondary tumors (Ebrahimi, Far, et al, 2023;Ebrahimi, Fardi, et al, 2023;Ebrahimi, Hakimzadeh et al, 2023;Minaei et al, 2023). Epigenetics can help to understand the mechanisms of commencement and progress of HCC; accordingly, it can be used for better designing therapeutic or diagnostic approaches (Pourhamzeh et al, 2023). The epigenetic processes can alter gene expression by modifying chromatin (Nebbioso et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Noncoding RNAs and programmed cell death in hepatocellular carcinoma: Significant role of epigenetic modifications in prognosis, chemoresistance, and tumor recurrence rate

Arefnezhad,

Ashna,

Rezaei‐Tazangi

et al. 2024

Cell Biology International

Self Cite

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most common type of liver cancer with a high death rate in the world. The molecular mechanisms related to the pathogenesis of HCC have not been precisely defined so far. Hence, this review aimed to address the potential cross‐talk between noncoding RNAs (ncRNAs) and programmed cell death in HCC. All related papers in the English language up to June 2023 were collected and screened. The searched keywords in scientific databases, including Scopus, PubMed, and Google Scholar, were HCC, ncRNAs, Epigenetic, Programmed cell death, Autophagy, Apoptosis, Ferroptosis, Chemoresistance, Tumor recurrence, Prognosis, and Prediction. According to the reports, ncRNAs, comprising long ncRNAs, microRNAs, circular RNAs, and small nucleolar RNAs can affect cell proliferation, migration, invasion, and metastasis, as well as cell death‐related processes, such as autophagy, ferroptosis, necroptosis, and apoptosis in HCC by regulating cancer‐associated genes and signaling pathways, for example, phosphoinositide 3‐kinase/Akt, extracellular signal‐regulated kinase/MAPK, and Wnt/β‐catenin signaling pathways. It seems that ncRNAs, as epigenetic regulators, can be utilized as biomarkers in diagnosis, prognosis, survival and recurrence rates prediction, chemoresistance, and evaluation of therapeutic response in HCC patients. However, more scientific evidence is suggested to be accomplished to confirm these results.

show abstract

Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma

Cited by 10 publications

References 137 publications

Blockade of PD‐1 and CTLA‐4: A potent immunotherapeutic approach for hepatocellular carcinoma

Blockade of PD‐1 and CTLA‐4: A potent immunotherapeutic approach for hepatocellular carcinoma

BSG Isoform 2 (ENST00000353555) Is a Better Component Than Total BSG Expression in Generating Prognostic Signature for Overall Survival of Liver Cancer

Noncoding RNAs and programmed cell death in hepatocellular carcinoma: Significant role of epigenetic modifications in prognosis, chemoresistance, and tumor recurrence rate

Contact Info

Product

Resources

About